Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Stock Price Up 3.1% – Time to Buy?

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s share price traded up 3.1% during trading on Friday. The stock traded as high as $0.71 and last traded at $0.7001. 15,720 shares changed hands during trading, a decline of 68% from the average session volume of 49,558 shares. The stock had previously closed at $0.6790.

Calidi Biotherapeutics Price Performance

The company has a debt-to-equity ratio of 0.24, a current ratio of 1.68 and a quick ratio of 1.68. The firm has a market cap of $1.86 million, a price-to-earnings ratio of -0.01 and a beta of 1.37. The business’s 50-day moving average price is $1.01 and its two-hundred day moving average price is $4.17.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($2.94) earnings per share (EPS) for the quarter.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc is a clinical-stage biotechnology company developing cell-based therapies designed to improve the treatment of cancer. The company’s approach uses allogeneic, or donor-derived, stem cells as delivery and support systems for therapeutic agents, with the goal of protecting and enhancing the activity of immune and other anti-cancer cells within tumors.

Calidi’s technology platforms include its SuperNova and NeuroNova programs. These platforms are intended to support the development of “off-the-shelf” cell therapies for solid tumors and other difficult-to-treat cancers.